Nakisa Khansari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nakisa Khansari has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Amir Mohammad Salehi
Fetal and Pediatric Cardiovascular Research Center, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Amirhossein Yazdi
Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2 shared publications - Maryam Mehrpooya
Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
2 shared publications Shahram Homayounfar
Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2 shared publications- Shahram Homayounfar
Department of Cardiology, School of Medicine, Clinical Research Development Unit of Farshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran
2 shared publications Akram Ranjbar
Department of Pharmacology and Toxicology School of Pharmacy Hamadan University of Medical Sciences Hamadan Iran
1 shared publication
Latest Publications
- 30 March 2026
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 26 (4) , 1-13
Assessment of the Association between Myocarditis (New-onset Heart Failure) and COVID-19 and COVID-19 Vaccination
Introduction: Myocarditis is a rare but significant cardiovascular complication that may occur after receiving COVID-19 vaccines, particularly in younger individuals. The majority of cases have been reported after receiving mRNA-based vaccines, while inactivated and viral vector-based vaccines have been associated with fewer occurrences. Despite this, myocarditis is much more common and results in a poorer prognosis following COVID-19 infection. However, the relationship between myocarditis post-vaccination and its potential mechanisms remains unclear due to limited information. Methods: This study investigated patients with myocarditis (new-onset heart failure) who had received the COVID-19 vaccine and those who had been infected with COVID-19 between March 2021 and March 2023 in Farshchian Cardiovascular Hospital in Hamedan. The data was analyzed using Stata version 14 software and Python. Results: Among 146 myocarditis patients, unvaccinated individuals had higher rates of hypertension, diabetes, obstructive pulmonary disease, and substance abuse, and exhibited more severe cardiac issues like mitral regurgitation and ventricular dysfunction. Vaccinated patients had better lab results and fewer severe symptoms. A model identified advanced age and cardiovascular dysfunction as key mortality risks, suggesting vaccination may mitigate severe cardiac complications and improve outcomes. Conclusion: The findings of this study show that although there is a risk of myocarditis as a side effect following the COVID-19 vaccination, its severity is far less than the occurrence following the COVID-19 infection, with fewer complications and a better prognosis. However, more studies are still necessary to complete the existing findings and clarify their unknown aspects.
- 30 March 2026
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 26 (4) , 1-13
Assessment of the Association between Myocarditis (New-onset Heart Failure) and COVID-19 and COVID-19 Vaccination
Introduction: Myocarditis is a rare but significant cardiovascular complication that may occur after receiving COVID-19 vaccines, particularly in younger individuals. The majority of cases have been reported after receiving mRNA-based vaccines, while inactivated and viral vector-based vaccines have been associated with fewer occurrences. Despite this, myocarditis is much more common and results in a poorer prognosis following COVID-19 infection. However, the relationship between myocarditis post-vaccination and its potential mechanisms remains unclear due to limited information. Methods: This study investigated patients with myocarditis (new-onset heart failure) who had received the COVID-19 vaccine and those who had been infected with COVID-19 between March 2021 and March 2023 in Farshchian Cardiovascular Hospital in Hamedan. The data was analyzed using Stata version 14 software and Python. Results: Among 146 myocarditis patients, unvaccinated individuals had higher rates of hypertension, diabetes, obstructive pulmonary disease, and substance abuse, and exhibited more severe cardiac issues like mitral regurgitation and ventricular dysfunction. Vaccinated patients had better lab results and fewer severe symptoms. A model identified advanced age and cardiovascular dysfunction as key mortality risks, suggesting vaccination may mitigate severe cardiac complications and improve outcomes. Conclusion: The findings of this study show that although there is a risk of myocarditis as a side effect following the COVID-19 vaccination, its severity is far less than the occurrence following the COVID-19 infection, with fewer complications and a better prognosis. However, more studies are still necessary to complete the existing findings and clarify their unknown aspects.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 136, 112072
Management of a recurrent suicide attempt with needle insertion into the heart; a case report
Penetrating cardiac injury (PCI) is rare and life-threatening, with complications that include hemorrhage, tamponade, arrhythmia, and cardiac arrest. Needle insertion into the heart is infrequently reported; to our knowledge, only one case of recurrent self-insertion has been described. A 29-year-old man with bipolar I disorder and a prior sternotomy for foreign-body removal presented after a second suicide attempt within two years, having self-inserted multiple needles through the chest and abdomen. Chest radiography showed three metallic densities in the left hemithorax and one in the abdominal wall. Transthoracic echocardiography demonstrated a linear metallic echo within the left ventricle (LV) near the apex. Computed tomography confirmed three metallic densities in the left thorax, one penetrating the LV to a depth of 30 mm. Median sternotomy was performed, and one needle was removed from the LV. After recovery, the patient was transferred to a psychiatric hospital for further inpatient treatment. Intentional cardiac injury by needle insertion is extremely rare and poses diagnostic and therapeutic challenges. Early imaging and prompt surgery are essential to reduce morbidity and mortality. A multidisciplinary plan, including psychiatric evaluation and follow-up, is required to prevent fatal outcomes and recurrence. This study describes the successful management of a penetrating cardiac injury in a patient with a prior sternotomy.
- 1 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 136, 112072
Open AccessManagement of a recurrent suicide attempt with needle insertion into the heart; a case report
Penetrating cardiac injury (PCI) is rare and life-threatening, with complications that include hemorrhage, tamponade, arrhythmia, and cardiac arrest. Needle insertion into the heart is infrequently reported; to our knowledge, only one case of recurrent self-insertion has been described. A 29-year-old man with bipolar I disorder and a prior sternotomy for foreign-body removal presented after a second suicide attempt within two years, having self-inserted multiple needles through the chest and abdomen. Chest radiography showed three metallic densities in the left hemithorax and one in the abdominal wall. Transthoracic echocardiography demonstrated a linear metallic echo within the left ventricle (LV) near the apex. Computed tomography confirmed three metallic densities in the left thorax, one penetrating the LV to a depth of 30 mm. Median sternotomy was performed, and one needle was removed from the LV. After recovery, the patient was transferred to a psychiatric hospital for further inpatient treatment. Intentional cardiac injury by needle insertion is extremely rare and poses diagnostic and therapeutic challenges. Early imaging and prompt surgery are essential to reduce morbidity and mortality. A multidisciplinary plan, including psychiatric evaluation and follow-up, is required to prevent fatal outcomes and recurrence. This study describes the successful management of a penetrating cardiac injury in a patient with a prior sternotomy.
- Open Access
- 27 September 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-7
Evaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon
Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram. The objective of this study was determined and compared left ventricle (LV)strain in patients with CSFP before and after receiving a high-dose atorvastatin. This cross-sectional study was conducted on 51 patients with CSFP from the beginning of 2021 to the end of September 2022. Trans-thoracic Echocardiogram (TTE) was performed by an echocardiography specialist. Thereafter, the patient’s basic information was entered into the researcher’s checklist after treatment with atorvastatin 40 mg daily for eight consecutive weeks. After eight weeks, the patients were subjected again to TTE. The data were analyzed in SPSS statistical software. The mean LV-GLS before taking atorvastatin was − 16.53%±3.63%. The mean LV-GLS after taking atorvastatin was 17.57%±3.53% (P.value = 0.01). The mean LV function before taking atorvastatin was 48.82%±9.19%. Meanwhile, the mean LV function after taking atorvastatin was 50.59%±7.91% (P = 0.01). There was no significantly change in left atrium volume (49.88 ± 0.68 vs. 49.9 + 0.67) after 8 weeks taking atorvastatin (P = 0.884). The plasma ET-1 levels are elevated in CSFP patients, and atorvastatin improves coronary flow and endothelial function. As evidenced by the results of this study, the daily intake of 40 mg of oral atorvastatin during eight consecutive weeks in patients with CSFP significantly improved LV strain and LV function, however atorvastatin does not have a significant effect on improving the right ventricular function and pulmonary artery systolic pressure.
- 27 September 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-7
Open AccessEvaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon
Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram. The objective of this study was determined and compared left ventricle (LV)strain in patients with CSFP before and after receiving a high-dose atorvastatin. This cross-sectional study was conducted on 51 patients with CSFP from the beginning of 2021 to the end of September 2022. Trans-thoracic Echocardiogram (TTE) was performed by an echocardiography specialist. Thereafter, the patient’s basic information was entered into the researcher’s checklist after treatment with atorvastatin 40 mg daily for eight consecutive weeks. After eight weeks, the patients were subjected again to TTE. The data were analyzed in SPSS statistical software. The mean LV-GLS before taking atorvastatin was − 16.53%±3.63%. The mean LV-GLS after taking atorvastatin was 17.57%±3.53% (P.value = 0.01). The mean LV function before taking atorvastatin was 48.82%±9.19%. Meanwhile, the mean LV function after taking atorvastatin was 50.59%±7.91% (P = 0.01). There was no significantly change in left atrium volume (49.88 ± 0.68 vs. 49.9 + 0.67) after 8 weeks taking atorvastatin (P = 0.884). The plasma ET-1 levels are elevated in CSFP patients, and atorvastatin improves coronary flow and endothelial function. As evidenced by the results of this study, the daily intake of 40 mg of oral atorvastatin during eight consecutive weeks in patients with CSFP significantly improved LV strain and LV function, however atorvastatin does not have a significant effect on improving the right ventricular function and pulmonary artery systolic pressure.
- 17 July 2024
- Published by Springer Nature in Journal of Echocardiography
- p. 1-9
Cardiac response to hypertension treatment: an advanced echocardiographic evaluation
Background Hypertension is the most common reversible cause of cardiovascular disease worldwide and more than one billion individuals suffer from the disease. Constant heart exposure to increased afterload progresses to maladaptive remodeling, leading to cardiac dysfunction. In this study, we aimed to evaluate cardiac function in response to hypertension treatment. Methods One hundred patients diagnosed with hypertension were evaluated two times, with 3 to 6 months intervals, before and after antihypertensive therapy. Patients underwent clinical and echocardiographic evaluation in both visits and the interest effect of antihypertensive therapy on cardiac function was studied. Results 58 men and 42 women with a mean age of 60.81 ± 11.8 years were studied. Mean systolic and diastolic pressure in the first visit was 163.05 ± 20.6 and 95.40 ± 10.4, respectively. On the second visit, mean systolic and diastolic pressure was 129.95 ± 10.4 and 82.35 ± 7.2 respectively (P value for both < 0.001). The mean value of Global Longitudinal Strain as the main parameter for evaluating left ventricular systolic function was -15.54% on the first visit and changed to -16.95% on the second visit (P value 0.025). Conclusions According to the results of this study, changes in parameters, indicator of systolic and diastolic function, after 3–6 months of antihypertensive therapy are significant. The most important point is that maladaptive remodeling of the heart is reversible if hypertension is diagnosed timely. To follow-up patients under antihypertensive therapy, GLS and parameters indicator of diastolic dysfunction, have the best diagnostic value in terms of detecting early stages of cardiac injury.
- 17 July 2024
- Published by Springer Nature in Journal of Echocardiography
- p. 1-9
Cardiac response to hypertension treatment: an advanced echocardiographic evaluation
Background Hypertension is the most common reversible cause of cardiovascular disease worldwide and more than one billion individuals suffer from the disease. Constant heart exposure to increased afterload progresses to maladaptive remodeling, leading to cardiac dysfunction. In this study, we aimed to evaluate cardiac function in response to hypertension treatment. Methods One hundred patients diagnosed with hypertension were evaluated two times, with 3 to 6 months intervals, before and after antihypertensive therapy. Patients underwent clinical and echocardiographic evaluation in both visits and the interest effect of antihypertensive therapy on cardiac function was studied. Results 58 men and 42 women with a mean age of 60.81 ± 11.8 years were studied. Mean systolic and diastolic pressure in the first visit was 163.05 ± 20.6 and 95.40 ± 10.4, respectively. On the second visit, mean systolic and diastolic pressure was 129.95 ± 10.4 and 82.35 ± 7.2 respectively (P value for both < 0.001). The mean value of Global Longitudinal Strain as the main parameter for evaluating left ventricular systolic function was -15.54% on the first visit and changed to -16.95% on the second visit (P value 0.025). Conclusions According to the results of this study, changes in parameters, indicator of systolic and diastolic function, after 3–6 months of antihypertensive therapy are significant. The most important point is that maladaptive remodeling of the heart is reversible if hypertension is diagnosed timely. To follow-up patients under antihypertensive therapy, GLS and parameters indicator of diastolic dysfunction, have the best diagnostic value in terms of detecting early stages of cardiac injury.
- Open Access
- 10 October 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (10) , e8033
The extremely rare case of aortic chordae tendineae strands: A case report with literature review
Key Clinical Message: The aortic chordae tendineae strands (ACTS) is a rare complication that can induce aortic regurgitation. Reported cases of ACTS are very few, and this is the first case reported in Iran. Patients with unexplained aortic regurgitation should be carefully evaluated for ACTS, which can be easily observed by TEE; a decision regarding aortic valve surgery should be made based on the severity of AR. Herein we reported A 64‐year‐old male was admitted to our hospital for dyspnea on exertion. In transthoracic Echocardiography a fibrous band‐like chordae in the aortic root attached to the noncoronary cusp of the aorta was seen, which caused retraction of the noncoronary cusp, mal‐coaptation of the aortic valves, and severe eccentric jet posterior directed aortic regurgitation. As a result of the ACTS, the patient was diagnosed with severe aortic regurgitation (AR); due to the symptomatic severe AR, the patient underwent aortic valve surgical replacement.
- 10 October 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (10) , e8033
Open AccessThe extremely rare case of aortic chordae tendineae strands: A case report with literature review
Key Clinical Message: The aortic chordae tendineae strands (ACTS) is a rare complication that can induce aortic regurgitation. Reported cases of ACTS are very few, and this is the first case reported in Iran. Patients with unexplained aortic regurgitation should be carefully evaluated for ACTS, which can be easily observed by TEE; a decision regarding aortic valve surgery should be made based on the severity of AR. Herein we reported A 64‐year‐old male was admitted to our hospital for dyspnea on exertion. In transthoracic Echocardiography a fibrous band‐like chordae in the aortic root attached to the noncoronary cusp of the aorta was seen, which caused retraction of the noncoronary cusp, mal‐coaptation of the aortic valves, and severe eccentric jet posterior directed aortic regurgitation. As a result of the ACTS, the patient was diagnosed with severe aortic regurgitation (AR); due to the symptomatic severe AR, the patient underwent aortic valve surgical replacement.
- Open Access
- 1 September 2022
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 18 (5) , 1
Idiopathic Pulmonary Artery Aneurysm: A Case Report
Background: Idiopathic pulmonary artery aneurysm is a rare disorder that has been reported in less than 50 cases. This complication is often asymptomatic, while the first manifestation can be severe hemoptysis or death. Case Presentation: A 36-year-old man presented to our institute with hemoptysis and fever. Dilated pulmonary artery trunk (5.5 cm) and the left pulmonary artery branch (6.90 cm) were discovered during a computed tomography angiogram scan in the patient's chest region. Therefore, the patient was diagnosed with a pulmonary artery aneurysm. According to the results of the tests requested for the patient, the cause of the patient's pulmonary artery aneurysm was not determined. Therefore, an idiopathic pulmonary artery aneurysm was proposed for the patient. Conclusion: Idiopathic pulmonary artery aneurysm poses a double diagnostic and therapeutic problem. The rarity of the disease, and the absence of specific clinical signs make diagnosis difficult.
- 1 September 2022
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 18 (5) , 1
Open AccessIdiopathic Pulmonary Artery Aneurysm: A Case Report
Background: Idiopathic pulmonary artery aneurysm is a rare disorder that has been reported in less than 50 cases. This complication is often asymptomatic, while the first manifestation can be severe hemoptysis or death. Case Presentation: A 36-year-old man presented to our institute with hemoptysis and fever. Dilated pulmonary artery trunk (5.5 cm) and the left pulmonary artery branch (6.90 cm) were discovered during a computed tomography angiogram scan in the patient's chest region. Therefore, the patient was diagnosed with a pulmonary artery aneurysm. According to the results of the tests requested for the patient, the cause of the patient's pulmonary artery aneurysm was not determined. Therefore, an idiopathic pulmonary artery aneurysm was proposed for the patient. Conclusion: Idiopathic pulmonary artery aneurysm poses a double diagnostic and therapeutic problem. The rarity of the disease, and the absence of specific clinical signs make diagnosis difficult.
- Open Access
- 20 June 2022
- Published by Springer Nature in Cardiology and Therapy
- Vol. 11 (3) , 421-432
Influence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy
Introduction Considering the anticoagulant actions of vitamin D, we hypothesize that vitamin D status might affect the required dose of warfarin for maintaining the therapeutic international normalized ratio (INR). Methods In a retrospective single-center cohort study, serum levels of 25-hydroxyvitamin D were assessed for 89 subjects receiving a stable dose of warfarin for 3 months or longer and had a stable INR between 2 and 3.5 for at least three consecutive visits. A warfarin sensitivity index (WSI), defined as the steady-state INR divided by the mean daily warfarin dose, was used for measuring the warfarin dose response. The relation between the serum level of 25-hydroxyvitamin D and WSI value and the difference in the mean WSI value between the subjects with different vitamin D status categories (sufficient, insufficient, and deficient) were assessed. Results Twenty-one subjects had vitamin D deficiency, 43 had vitamin D insufficiency, and only 25 had normal levels of 25-hydroxyvitamin D. Based on the multiple linear regression analysis, there was a significant but weakly positive correlation between WSI and 25-hydroxyvitamin D serum levels, as the value of WSI increases by almost 0.0027434 for every unit increase in 25-hydroxyvitamin D serum level (p value = 0.041). Using one-way ANOVA analysis, there was a trend in a significant difference between the groups with different vitamin D status categories regarding the mean WSI value (F = 2.95, p value = 0.057), as subjects with sufficient vitamin D state compared to those with vitamin D deficiency had a higher WSI value. Conclusions Although the study’s limitations limit our ability to draw definite conclusions, the present data suggest that in addition to other traditional factors, vitamin D status might also affect warfarin sensitivity and maintenance dose requirement. However, to more clearly explain this link, further studies with high involvement subjects are required.
- 20 June 2022
- Published by Springer Nature in Cardiology and Therapy
- Vol. 11 (3) , 421-432
Open AccessInfluence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy
Introduction Considering the anticoagulant actions of vitamin D, we hypothesize that vitamin D status might affect the required dose of warfarin for maintaining the therapeutic international normalized ratio (INR). Methods In a retrospective single-center cohort study, serum levels of 25-hydroxyvitamin D were assessed for 89 subjects receiving a stable dose of warfarin for 3 months or longer and had a stable INR between 2 and 3.5 for at least three consecutive visits. A warfarin sensitivity index (WSI), defined as the steady-state INR divided by the mean daily warfarin dose, was used for measuring the warfarin dose response. The relation between the serum level of 25-hydroxyvitamin D and WSI value and the difference in the mean WSI value between the subjects with different vitamin D status categories (sufficient, insufficient, and deficient) were assessed. Results Twenty-one subjects had vitamin D deficiency, 43 had vitamin D insufficiency, and only 25 had normal levels of 25-hydroxyvitamin D. Based on the multiple linear regression analysis, there was a significant but weakly positive correlation between WSI and 25-hydroxyvitamin D serum levels, as the value of WSI increases by almost 0.0027434 for every unit increase in 25-hydroxyvitamin D serum level (p value = 0.041). Using one-way ANOVA analysis, there was a trend in a significant difference between the groups with different vitamin D status categories regarding the mean WSI value (F = 2.95, p value = 0.057), as subjects with sufficient vitamin D state compared to those with vitamin D deficiency had a higher WSI value. Conclusions Although the study’s limitations limit our ability to draw definite conclusions, the present data suggest that in addition to other traditional factors, vitamin D status might also affect warfarin sensitivity and maintenance dose requirement. However, to more clearly explain this link, further studies with high involvement subjects are required.
- Open Access
- 1 June 2022
- Published by CMV Verlag in Avicenna Journal of Clinical Medicine
- Vol. 29 (1) , 18-25
Evaluation of Advanced Echocardiographic Parameters of Right Ventricular in Patients with Pulmonary Hypertension
Background and Objective: Pulmonary hypertension is an increase in blood pressure of the pulmonary artery which leads to right ventricular dysfunction. Therefore, the present study aimed to compare echocardiographic parameters in the study of right ventricular failure in patients with pulmonary hypertension. Materials and Methods: In the present descriptive cross-sectional ...
- 1 June 2022
- Published by CMV Verlag in Avicenna Journal of Clinical Medicine
- Vol. 29 (1) , 18-25
Open AccessEvaluation of Advanced Echocardiographic Parameters of Right Ventricular in Patients with Pulmonary Hypertension
Background and Objective: Pulmonary hypertension is an increase in blood pressure of the pulmonary artery which leads to right ventricular dysfunction. Therefore, the present study aimed to compare echocardiographic parameters in the study of right ventricular failure in patients with pulmonary hypertension. Materials and Methods: In the present descriptive cross-sectional ...
- 2 November 2021
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 191 (5) , 2063-2075
Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure
Background This research attempted to assess whether N-acetylcysteine (NAC) as adjunctive therapy can be useful in the treatment of patients with heart failure (HF). Methods Fifty-five cases with diagnosed systolic HF and stable symptomatic New York Heart Association (NYHA) functional class II and III and on optimal medical treatment of HF for at least 3 months were assigned for receiving oral NAC (600 mg twice daily) or placebo for 12 weeks. The outcomes were changes in the echocardiographic hemodynamic indices as well as the patients’ functional capacity assessed by NYHA classification over a 12-week treatment. Results Compared to placebo, NAC more significantly improved the systolic left ventricular (LV) function expressed as the ejection fraction and Tei index. These changes are accompanied by more improvement in other LV echocardiographic indices including LV end-diastolic volume index and LV global longitudinal strain in the patients receiving NAC in comparison with those receiving placebo. In parallel with the improvement of LV function, right ventricular (RV) function expressed as RV fractional area change and RV Tei-index also got more improvement in those receiving NAC than those receiving placebo. However, the change in RV global longitudinal strain did not show a significant difference between study groups. Additionally, at week 12, the distribution of the NYHA functional class also shifted toward a better outcome in the NAC group in comparison with the placebo group; however, it was not significant. Conclusions These preliminary data support experimental findings showing that NAC supplementation is able to improve heart function. Trial registration The registration of the trial was done at the Iranian Registry of Clinical Trials (www.irct.ir). Identifier code: IRCT20120215009014N333. Registration date: 2020–01-11.
- 2 November 2021
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 191 (5) , 2063-2075
Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure
Background This research attempted to assess whether N-acetylcysteine (NAC) as adjunctive therapy can be useful in the treatment of patients with heart failure (HF). Methods Fifty-five cases with diagnosed systolic HF and stable symptomatic New York Heart Association (NYHA) functional class II and III and on optimal medical treatment of HF for at least 3 months were assigned for receiving oral NAC (600 mg twice daily) or placebo for 12 weeks. The outcomes were changes in the echocardiographic hemodynamic indices as well as the patients’ functional capacity assessed by NYHA classification over a 12-week treatment. Results Compared to placebo, NAC more significantly improved the systolic left ventricular (LV) function expressed as the ejection fraction and Tei index. These changes are accompanied by more improvement in other LV echocardiographic indices including LV end-diastolic volume index and LV global longitudinal strain in the patients receiving NAC in comparison with those receiving placebo. In parallel with the improvement of LV function, right ventricular (RV) function expressed as RV fractional area change and RV Tei-index also got more improvement in those receiving NAC than those receiving placebo. However, the change in RV global longitudinal strain did not show a significant difference between study groups. Additionally, at week 12, the distribution of the NYHA functional class also shifted toward a better outcome in the NAC group in comparison with the placebo group; however, it was not significant. Conclusions These preliminary data support experimental findings showing that NAC supplementation is able to improve heart function. Trial registration The registration of the trial was done at the Iranian Registry of Clinical Trials (www.irct.ir). Identifier code: IRCT20120215009014N333. Registration date: 2020–01-11.